


Para-aminoblebbistatin

Cat. No. ax494682



Product Specification

(S)-1-(4-Amino-phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-pyrrolo[2,3-b]quinolin-4-one

Parameter	Results
M.w	307
Storage	-20
Chemical purity	>95%
Ratio of enantiomer	>90%
Cytotoxicity	Not cytotoxic in the dark
Extinction coeff at 427 nm	M-1cm-1 (pH 7.3)

Recommendations For Use

1. Solubility: The equilibrium concentration of para-aminoblebbistatin is 300-420 uM in water based buffers containing 0.1%-1% DMSO. For the concentration of DMSO stocks, we recommend 50 mM.
2. Photostability: unlike blebbistatin, para-aminoblebbistatin is not phototoxic when irradiated with >440 nm wavelength light.
3. Freeze thaw: limit freeze-thawing cycles.

Myosin Inhibition

Myosin Type	Inhibitory Properties
Rabbit skeletal muscle myosin S1 basal ATPase activity	100% inhibition IC ₅₀ : ~1.3 μM
Rabbit skeletal muscle myosin S1 actin activated ATPase activity	100% inhibition IC ₅₀ : ~0.47 μM
<i>Dictyostelium discoideum</i> myosin II motor domain actin activated ATPase activity	80% inhibition IC ₅₀ ~6.6 μM
<i>Dictyostelium discoideum</i> myosin II motor domain basal ATPase activity	90 % inhibition IC ₅₀ : ~6.7 μM
Human, slow-twitch muscle fiber (beta myosin)	>95% inhibition IC ₅₀ : ~11 μM
pig left ventricle, isolated cardiac myosin ATPase activity (unpublished data)	>92% inhibition IC ₅₀ : 5.2 μM

Usage Statement

Our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans.

Ethics Statement

Primary cell and primary cell-derived products sold by Axol Bioscience are obtained with fully informed consent including consent for commercial use from the donor or donor's next-of-kin. An independent Ethics Committee or Institutional Review Board approved the donor consent forms. The anonymized cells/tissue are collected under protocols that are in compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the Declaration of Helsinki or Human Tissue Act, as appropriate. The collection protocol of sample material must comply with all international, national and local laws. Axol Bioscience works through tissue acquisition networks, physicians and organizations that are compliant with these standards.

QC Review

Reviewer	Position	Signature	Date
Rob Treanor	Head of Supply		May 2018